Bionexus Gene Lab Corp (BGLC) Stock Price & Analysis
Bionexus Gene Lab Corp (BGLC) fell 2.69% to USD 1.45 as of September 8, 2026 at 06:57 UTC, according to Nexqual real-time market data.
BGLC last closed at USD 1.45; the session ranged USD 1.39–1.45 on volume of 740 shares. Market capitalization is —, with a 52-week range of USD 1.07–6.1 (NCM). Source: Nexqual, September 8, 2026 at 06:57 UTC.
Key Statistics (as of September 8, 2026 at 06:57 UTC)
| Price | USD 1.45 |
|---|---|
| Change | ▼ 2.69% (down) |
| Previous Close | USD 1.45 |
| Open | USD 1.45 |
| Day Range | USD 1.39 – 1.45 |
| 52-Week Range | USD 1.07 – 6.1 |
| Volume | 740 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (BGLC)
Nexqual's technical model rates BGLC "STRONG SELL" based on 0 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 06:57 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 41.01 (neutral) |
| vs SMA50 | Below (USD 1.62) |
| MACD | -0.04 (negative) |
From Bionexus Gene Lab Corp's Latest SEC 10-K Filing (filed 2026-04-14)
Key Strengths & Strategy (as disclosed to the SEC)
- Our proprietary algorithm software then analyzes this collected data and processes checked by the laboratory manager to ensure all the steps are followed in the deriving predictive model for each disease condition.
- By identifying disease-specific gene activity patterns, we can develop screening tools that enable early detection, monitor disease progression, and support precision interventions.   We take advantage of profiling these changes, which enables us to identify unique molecular signatures (biomarkers) reflecting disease activity which can then be used to develop disease-specific molecular diagnostic assays.
Partnerships
- MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management.   In November 2025, the Company entered into a Share Subscription and Shareholders' Agreement with Fidelion Diagnostics Pte.
- The Company continues to evaluate MRNA Scientific's operations, commercial opportunities, and strategic direction.   In November 2025, the Company completed a Share Subscription and Shareholders' Agreement with Fidelion Diagnostics Pte.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ARBB | ARB IOT Group Limited | USD 4.41 | ▲ 1.38% |
| ZVSA | ZyVersa Therapeutics, Inc. | USD 0.1 | ▲ 4.04% |
| MGIH | Millennium Group International | USD 1.53 | ▲ 0.66% |
| OMH | Ohmyhome Limited | USD 2.86 | ▼ 10.34% |
| VCIG | VCI Global Limited | USD 1.82 | ▼ 0.55% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:57 UTC. This page is informational and not investment advice.